Gyre Therapeutics (NASDAQ:GYRE) Trading Down 3.8% – Time to Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s stock price was down 3.8% during trading on Tuesday . The stock traded as low as $13.61 and last traded at $13.61. Approximately 1,520 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 69,687 shares. The stock had previously closed at $14.15.

Gyre Therapeutics Price Performance

The business’s 50 day moving average is $12.95 and its 200 day moving average is $13.13.

Gyre Therapeutics (NASDAQ:GYRE) last issued its earnings results on Tuesday, August 13th. The company reported $0.01 EPS for the quarter. The business had revenue of $25.23 million during the quarter. Analysts forecast that Gyre Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Gyre Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of GYRE. WINTON GROUP Ltd acquired a new stake in shares of Gyre Therapeutics during the second quarter worth approximately $220,000. Bank of New York Mellon Corp purchased a new stake in Gyre Therapeutics in the 2nd quarter worth approximately $218,000. Renaissance Technologies LLC acquired a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at $166,000. Finally, Rhumbline Advisers purchased a new position in shares of Gyre Therapeutics during the 2nd quarter valued at $123,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.